GPOL is the engine that drives Precision-Panc. GPOL’s bespoke pancreatic cancer panel allows fast turn-around of clinical sequencing and delivers high-quality data on all classes of clinically relevant alterations. The assay content is then expertly analysed and reported back to site clinicians.
This will allow biomarker-driven clinical studies (PRIMUS trials) to be integrated into the NHS clinical research pathway without delaying patient treatment.
There are currently two PRIMUS studies recruiting, PRIMUS 001 which looks at patients with metastatic disease and PRIMUS 002 which is in the neo-adjuvant setting. One PRIMUS study, PRIMUS 003 has completed recruitment and data analysis is underway and there are several other PRIMUS studies in development, including PRIMUS 004, that looks at patients who have already had one treatment for their metastatic disease and PRIMUS 005 that will be in the locally advanced setting.
